How to read a line
- Clinical-trial and label language is named as such on the compound page.
- Forum notes are not rates. A common story is still an anecdote.
- No trials is not a safety file. Absence of a report is not absence of harm.
Reported effects
What shows up. What should stop you.
Drawn from drug labels where a drug exists, and from published reports plus the pattern of anecdote where it doesn’t. Incomplete on purpose. Not a management plan, and not a reason to start.
Risks that are not a dose chart
- Peptides can be immunogenic. That is a class problem, not a measured rate on this page.
- Contamination and aggregation are product-quality failures, separate from the molecule’s pharmacology.
- Incretin labels carry gastrointestinal and gallbladder warnings. Those belong to the licensed products.
- Long-term exposure for unapproved materials is not established here. No interaction list is invented to fill that gap.
Stop and get care
- Trouble breathing, swelling of the face or throat, or a spreading rash after an exposure. That is emergency care, not a lower amount next time.
- Severe, persistent upper-abdominal pain, especially through to the back, on an incretin. Pancreatitis is on those labels.
- Chest pain, fainting, or a heart rate that stays high and will not settle.
- Sudden vision change.
- Sweating, confusion, and not making sense — think low blood sugar, particularly around IGF-1 analogs. If the person can swallow safely, sugar; then medical help.
- A mole that changes, bleeds, or itches after a melanocortin. Dermatology, not a forum.
- A solution that has gone cloudy, colored when it shouldn’t be, or particulate. Do not use it.
Repair
- BPC-157
- In anecdote it is usually described as uneventful.
- Nausea shows up more often when people discuss oral material.
- TB-500
- Discussion usually describes it as well tolerated, with local irritation the common complaint.
- Headache and a tired feeling show up less often.
- BPC-157 / TB-500
- Reports follow the components: mostly quiet, sometimes local irritation, sometimes nausea.
- You cannot attribute an effect to one half of an unlabeled mix.
- KPV
- Little is consistently reported. That is a lack of data, not evidence of safety.
- It should not darken skin the way melanotan II does. If a vial does, it is probably not KPV.
- KLOW
- Expect the reported notes of whichever ingredients are actually present. GHK-Cu turns the solution blue. If a “copper blend” is colorless, ask questions.
- Local sting is common when GHK-Cu is a large fraction of the mass.
Metabolic
- Semaglutide
- Nausea, vomiting, constipation, and diarrhea are the labeled center of the adverse-event table, worst during escalation.
- Gallbladder disease, pancreatitis, and possible worsening of diabetic retinopathy are labeled concerns.
- Tirzepatide
- Nausea, diarrhea, decreased appetite, vomiting, and constipation dominate the label.
- Gallbladder events and pancreatitis are in the warnings.
- Retatrutide
- Nausea and other GI effects, as with the rest of this class.
- Heart-rate elevation was notable in published trial data.
- AOD-9604
- Trial writeups generally described it as tolerated, which is not the same as effective.
- Local irritation is the anecdotal note.
GH axis
- CJC-1295 / Ipamorelin
- Water retention and a tight or tingling feeling in the hands show up often in discussion of GH secretagogues.
- Flushing or a head rush right after a measure is commonly described.
- CJC-1295 (no DAC)
- Flushing, warmth, and lightheadedness are the usual immediate notes.
- Water retention is discussed when it is paired with a GHRP over weeks.
- Ipamorelin
- Generally described as milder than GHRP-2 or GHRP-6.
- Head rush, flushing, and mild water retention still come up.
- Sermorelin
- Flushing and injection-site irritation are the notes that repeat in the old clinical literature.
- It is discussed as “cleaner but shorter” than the modified fragments.
- Tesamorelin
- The label describes joint pain, limb pain, swelling, and injection-site reactions as common.
- Glucose can move the wrong way. The approved product is contraindicated in people with active cancer, and in pregnancy.
Neuro
Longevity
- MOTS-c
- Anecdote is thin and inconsistent: sometimes nothing, sometimes a flushed or wired feeling.
- Lack of horror stories is not a safety file.
- NAD+
- Rapid IV administration is famous for flushing, chest pressure, nausea, and cramping. Slower delivery is how clinics try to avoid that. This page is not an IV manual.
- Headache and a wired or insomnia-prone feeling are described afterward.
- SS-31
- Injection-site reactions were the repeating note in clinical work.
- Eosinophilia showed up in some development programs and is why “it’s just a mitochondrial peptide” is a lazy sentence.
- Thymosin α1
- The clinical record is relatively quiet: local irritation, occasional fatigue, rare allergic reactions.
- Quiet is not permission. Immune-active peptides are a bad idea to freelance during an active malignancy or a serious infection without a physician who already owns that problem.
- Epitalon
- Anecdote is sparse. Sleep changes are the note people reach for, which may be expectation.
- There is no credible side-effect table comparable to an FDA label.
Signal
- GHK-Cu
- The solution is blue to purple when the copper complex is real. A white cake that stays colorless in water deserves a skeptical COA.
- Local sting and redness are the common notes.
- PT-141
- Nausea and flushing are very common on the label.
- Headache and injection-site reactions.
- Melanotan II
- Nausea and flushing, often strong.
- Spontaneous erections.
- IGF-1 LR3
- Sweating, shaking, hunger, and confusion — low blood sugar — are the effect to take seriously.
- Jaw pain, water retention, and a hypoglycemic headache circulate in anecdote.